XF Pipeline Update Meeting
Tuesday October 17, 2023
Tuesday October 17, 2023
Destiny Pharma plc
(“Destiny Pharma” or “the Company”)
XF Pipeline Update Meeting with Leading Experts and New Microbiological Data on XF-73
Brighton, United Kingdom – 17 October 2023 – Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology
company focused on the development and commercialisation of novel medicines to prevent life threatening infections,
confirms that it is hosting a meeting for analysts and investors on its XF product pipeline later today at 2:00pm BST /
9:00am EDT.
The meeting will feature updates from Destiny Pharma leadership and presentations from leading experts, as well as
an interview with a UK patient.
Leadership updates will detail the commercial opportunity for XF-73 nasal, including an analysis of the addressable
market, and updates on the XF platform, pipeline and potential, including new microbiological data demonstrating the
effectiveness of XF-73 against all known antibiotic strains of Staphylococcus.
Leading experts will give the following presentations and discussions:
· Professor Mark Wilcox, consultant microbiologist and head of R&D in microbiology at the Leeds Teaching
Hospital, and Richard Proctor, Professor Emeritus of Medicine and Medical Microbiology and Immunology at
the University of Wisconsin-Madison, will present the issue of surgical site infections and their impact on
healthcare systems
· Dr Alex Mericli, Associate Professor and Plastic Surgeon at MD Anderson Cancer Center and Mr Raghbir
Khakha, Consultant Trauma and Orthopaedic Surgeon at Guy’s and St Thomas’s Hospital will present the
reality on the wards
The meeting will also include an interview with a UK patient who became infected with Staph. aureus following
surgery for a torn anterior cruciate ligament.
Commenting on the event, Chris Tovey, Chief Executive Officer, Destiny Pharma, said:
“The potential of XF-73 nasal is one of the reasons I was motivated to join Destiny Pharma in its mission to reduce
the emergence and impact of drug resistant pathogens with preventative solutions.
“The innovative XF platform includes a blockbuster, $2bn plus opportunity in the US alone, but has also shown utility
beyond surgical site infections to address fungal and dermal infections as well. Most importantly, it has the potential
to play an essential role in protecting vulnerable patients, and in doing so, save lives.”
The meeting will be held in person at the offices of Cavendish, 1 Bartholomew Close, London, EC1A 7BL, alongside
the option of virtual attendance via the Investor Meet platform. Prior registration for the event is required. To attend in
person please contact RD@destinypharma.com.
For further information, please contact:
Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0) 127 370 4440
pressoffice@destinypharma.com
Powerscourt Group
Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher Ward
+44 (0) 20 7250 1446
Destiny@powerscourt-group.com
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance
Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
About Destiny Pharma
Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and
commercialisation of novel medicines that can prevent life-threatening infections. The company’s drug development
pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.
difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal
gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.